Market Eyes LiveHealthcare Stocks, Rated
Healthcare spans large pharmaceutical companies, device makers, diagnostics, distributors and insurers. Demand is among the least cyclical in the market, which is why the sector is treated as defensive, but the policy risk is among the highest.
Every score below is free. 20 healthcare stocks scored on the same eight factors, updated as the data changes.
Ranked by composite score
Ranked highest to lowest by MELANY composite score, a 0 to 100 reading from eight factors. Each row links to the full breakdown and the live price. Ratings are a dated snapshot, most recently computed 2026-08-21.
These tiers are algorithmic research readings, not a recommendation to buy or sell any security, and not personalized investment advice. Ranking order is not a suggested purchase order.
What is in the app for these 20 companies
The score and the eight factors behind it are open on every company page. The trade plan is the part that is not: one suggested entry price per company, the stop, the targets, and an alert when a name enters its entry zone. That unlocks free when you create an account.
What changed in the past month
11 of 20 companies in this group have a scoring history going back a month, and 10 of those changed. The 8 largest moves are below: 8 lower.
- -13Merck & Co., Inc. (MRK): Highest Conviction to Promising, score fell 13 points to 61.
- -9Pfizer Inc. (PFE): score fell 9 points to 68.
- -8ABBVIE INC. (ABBV): score fell 8 points to 70.
- -8Vertex Pharmaceuticals Inc (VRTX): now flagged Runner!, a separate short-term momentum flag rather than a step up or down, with its score fell 8 points to 60.
- -6Regeneron Pharmaceuticals Inc (REGN): score fell 6 points to 66.
- -3Bristol-Myers Squibb Co. (BMY): score fell 3 points to 74.
- -3Eli Lilly & Co. (LLY): score fell 3 points to 67.
- -3UNITEDHEALTH GROUP INCORPORATED (UNH): Favorable to Hold, score fell 3 points to 63.
Measured against each company's rating about 30 days ago. A tier change is reported as a move between named tiers; the score is what carries the direction. Runner is a short-term momentum flag, not a rung above or below any other tier.
What moves this group
Patent expiry is the dominant long-term driver for pharmaceutical companies: a large product losing exclusivity can remove years of growth. Device makers follow procedure volumes and hospital capital budgets. Insurers are driven by the medical loss ratio, which is how much of each premium dollar goes out as claims. Drug pricing policy is the sector-wide risk.
Also searched as: healthcare sector stocks, pharmaceutical companies, medical device makers, health insurers.
How Market Eyes Live scores these companies
Every company on this page is scored by MELANY, our own engine, which reads regulatory filings and market data and produces a composite score from 0 to 100 across eight factors: valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile and macro fit.
Each score maps to a conviction tier rather than a buy or sell call. Established companies with enough financial history are judged on fundamentals. Pre-profit or thin-data companies are judged on a separate speculative path that leans on momentum and theme strength, because there are not enough fundamentals to read. That is why two names with similar scores can carry very different risk.
Frequently asked questions
Is healthcare a defensive sector?
Demand is relatively stable through the economic cycle, which is the usual reason for calling it defensive. That does not make individual names low risk, particularly around patent expiry and policy changes.
What is a patent cliff?
The point where a drug loses exclusivity and generic competition removes most of its revenue. It is the single largest scheduled risk in large-cap pharma.
How current is this list?
Each row shows the date its rating was computed, and the list refreshes on a rolling schedule.
Free account, no card. The scores stay free; the entry prices unlock.